SCHEMBL4024228

SCHEMBL4024228

Cc1c(F)cccc1C1[C@@H](C(=O)c2cccc(O)c2)CN(C(=O)C(C)C2CCCNC2)C[C@@H]1C(=O)c1cccc(O)c1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KAT7 O95251 1/20 0.33
RPLP1 P05386 1/20 0.33
RPLP0 P05388 1/20 0.33
RPS17 P08708 1/20 0.33
RPSA P08865 1/20 0.33
RPS2 P15880 1/20 0.33
RPL35A P18077 1/20 0.33
RPL7 P18124 1/20 0.33
RPL17 P18621 1/20 0.33
RPS4Y1 P22090 1/20 0.33
RPS3 P23396 1/20 0.33
RPS12 P25398 1/20 0.33
RPL13 P26373 1/20 0.33
RPL10 P27635 1/20 0.33
RPL12 P30050 1/20 0.33
RPL9; RPL9P7; RPL9P8; RPL9P9 P32969 1/20 0.33
RPL22 P35268 1/20 0.33
RPL4 P36578 1/20 0.33
RPS19 P39019 1/20 0.33
RPL3 P39023 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4024700 0.85 MGLL (0.35) RPLP1RPLP0RPS17RPSARPS2
SCHEMBL4018745 0.84 CXCR2 (0.35) RPLP1RPLP0RPS17RPSARPS2
SCHEMBL4018815 0.81 KDM2B (0.38) KCNH2
SCHEMBL4020652 0.80 MGLL (0.32) KCNH2MGLL
SCHEMBL4021116 0.80 SLC6A2 (0.35) SLC6A2SLC6A4SLC6A3MGLLCXCR2
SCHEMBL4018846 0.79 MGLL (0.36) KCNH2MGLL
SCHEMBL4025189 0.78 MGLL (0.38) MGLL
SCHEMBL4023658 0.78 MGLL (0.38) MGLL
SCHEMBL4025192 0.78 MGLL (0.38) MGLL
SCHEMBL4023656 0.78 MGLL (0.38) MGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7572814-B2 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds CYTOKINETICS, INCORPORATED (US) 2009-08-11 US claimed
US-7572814-B2 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds CYTOKINETICS, INCORPORATED (US) 2009-08-11 US disclosed
US-20070161674-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2007-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161674-A1 Certain chemical entities, compositions, and methods TP53, VHL, RB1 KAT7 2837/4885RPLP1 2304/4885RPLP0 1850/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.